James Vredenburgh, MD
About
Research
Publications
2023
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L, Yung W, Paleologos N, Nicholas M, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal Of Clinical Oncology 2023, 41: 4945-4952. PMID: 37935104, DOI: 10.1200/jco.22.02772.Peer-Reviewed Original ResearchBevacizumab alone groupObjective response rateIrinotecan groupRecurrent glioblastomaResponse rateMedian overall survival timeProgression-free survival ratesEnd pointEfficacy of bevacizumabIndependent radiology reviewPrimary end pointSecondary end pointsProgression-free survivalOverall survival timeExperienced gradeNoncomparative trialsOverall survivalPatients patientsAdverse eventsRadiology reviewIntracranial hemorrhageBevacizumabSurvival timePatientsIrinotecan
1994
Clostridium septicum abscess in hepatic metastases: successful medical management.
Thel M, Ciaccia D, Vredenburgh J, Peters W, Corey G. Clostridium septicum abscess in hepatic metastases: successful medical management. Bone Marrow Transplantation 1994, 13: 495-6. PMID: 7517261.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBone Marrow TransplantationBreast NeoplasmsCarmustineCeftazidimeCisplatinClindamycinClostridium InfectionsCombined Modality TherapyCyclophosphamideDoxorubicinDrug Therapy, CombinationEtoposideFemaleFluorouracilGasesGranulocyte Colony-Stimulating FactorHumansImipenemImmunocompromised HostLiver AbscessLiver NeoplasmsMethotrexateNeutropeniaSepsisConceptsHepatic metastasesMetastatic breast cancer treated with high-dose chemotherapyClostridium septicum bacteremiaHigh-dose chemotherapyBone marrow transplantationMarrow transplantationStandard therapySurgical debridementColonic malignancyMedical managementBacteremiaMetastasisExcess mortalityAntibioticsNeutropeniaChemotherapyAbscessMalignancyDebridementTransplantationTherapyPathophysiologyPatientsInfectionGangrene
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date02/01/2023Recruiting ParticipantsA Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024Recruiting ParticipantsA Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
HIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027Recruiting ParticipantsAn Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
HIC ID2000022049RoleSub InvestigatorPrimary Completion Date08/31/2026Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting Participants
Links & Media
News
- June 02, 2021
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as Connecticut Magazine 'Best Doctors'
- June 04, 2020
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine Best Doctors
- June 03, 2019
Yale Cancer Center and Smilow Cancer Hospital physicians recognized as CT Magazine 'Best Doctors'
- April 13, 2018
Connecticut Magazine recognizes Yale Cancer Center and Smilow Cancer Hospital physicians as 'Best Doctors'